Paul Bruno is the Chief Business Officer at Atavistik Bio. Paul was most recently the Senior Vice President of Business and Corporate Development at Fulcrum Therapeutics, where he was responsible for corporate strategy, business development, program leadership, and alliance management. While at Fulcrum, Paul successfully executed several licensing and financing transactions, including the collaboration and license agreement with Sanofi in May 2024. Prior to Fulcrum, he was at ClearView Healthcare Partners, a life sciences strategy firm that specializes in working with biotech, pharma, and medtech companies. At ClearView, Paul worked with clients on corporate strategy, portfolio management, pipeline prioritization, and business development engagements. Paul completed a postdoctoral fellowship at Boston Children’s Hospital, where he focused on identifying fetal hemoglobin inducers for sickle cell disease and β-thalassemia. He also brings entrepreneurial experience, having previously co-founded and raised seed funding for an early-stage materials company.
Paul received his PhD in chemistry from the University of Michigan and a BS from Santa Clara University, where he double majored in chemistry and public health.